Search Results - "Bursi, Roberta"

Derivation and Validation of Toxicophores for Mutagenicity Prediction by Kazius, Jeroen, McGuire, Ross, Bursi, Roberta

“…Mutagenicity is one of the numerous adverse properties of a compound that hampers its potential to become a marketable drug. Toxic properties can often be…”
Get full text

In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim by Sips, Fianne L P, Pappalardo, Francesco, Russo, Giulia, Bursi, Roberta

“…The last few decades have seen the approval of many new treatment options for Relapsing-Remitting Multiple Sclerosis (RRMS), as well as advances in diagnostic…”
Get full text

Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility by Musuamba, Flora T., Skottheim Rusten, Ine, Lesage, Raphaëlle, Russo, Giulia, Bursi, Roberta, Emili, Luca, Wangorsch, Gaby, Manolis, Efthymios, Karlsson, Kristin E., Kulesza, Alexander, Courcelles, Eulalie, Boissel, Jean‐Pierre, Rousseau, Cécile F., Voisin, Emmanuelle M., Alessandrello, Rossana, Curado, Nuno, Dall’ara, Enrico, Rodriguez, Blanca, Pappalardo, Francesco, Geris, Liesbet

“…The value of in silico methods in drug development and evaluation has been demonstrated repeatedly and convincingly. While their benefits are now unanimously…”
Get full text

Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation by Maleki, Avisa, Crispino, Elena, Italia, Serena Anna, Di Salvatore, Valentina, Chiacchio, Maria Assunta, Sips, Fianne, Bursi, Roberta, Russo, Giulia, Maimone, Davide, Pappalardo, Francesco

“…Multiple sclerosis is an autoimmune inflammatory disease that affects the central nervous system through chronic demyelination and loss of oligodendrocytes…”
Get full text

Verifying and Validating Quantitative Systems Pharmacology and In Silico Models in Drug Development: Current Needs, Gaps, and Challenges by Musuamba, Flora T., Bursi, Roberta, Manolis, Efthymios, Karlsson, Kristin, Kulesza, Alexander, Courcelles, Eulalie, Boissel, Jean‐Pierre, Lesage, Raphaëlle, Crozatier, Cécile, Voisin, Emmanuelle M., Rousseau, Cécile F., Marchal, Thierry, Alessandrello, Rossana, Geris, Liesbet

“…The added value of in silico models (including quantitative systems pharmacology models) for drug development is now unanimously recognized. It is, therefore,…”
Get full text

ADPKD Predictor: A Cloud-Based Prognostic Tool for Autosomal Dominant Polycystic Kidney Disease: FR-PO004 by Carbone, Vincenzo, Gazzin, Matteo, Bursi, Roberta, Magistroni, Riccardo, Corsi, Cristiana

Get full text

3390 ADPKD PREDICTOR: A CLOUD-BASED PROGNOSTIC TOOL FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE by Carbone, Vincenzo, Gazzin, Matteo, Bursi, Roberta, Magistroni, Riccardo, Corsi, Cristiana

“…Abstract Background and Aims ADPKD is a progressively debilitating genetic disease characterized by the growth of numerous cysts in the kidneys, leading…”
Get full text

ADPKD Segmentator: A Cloud-Based Prognostic Tool for Autosomal Dominant Polycystic Kidney Disease: SA-PO007 by Carbone, Vincenzo, Baretta, Alessia, Corsi, Cristiana, Bursi, Roberta

Get full text

Accelerating Digitalization in Healthcare with the InSilicoTrials Cloud-Based Platform: Four Use Cases by Nicolò, Chiara, Sips, Fianne, Vaghi, Cristina, Baretta, Alessia, Carbone, Vincenzo, Emili, Luca, Bursi, Roberta

“…The use of in silico trials is expected to play an increasingly important role in the development and regulatory evaluation of new medical products. Among the…”
Get full text

STRhiPS: A safety trials tool based on human-induced pluripotent stem cells to evaluate drug-induced arrhythmias by Severi, Stefano, Paci, Michelangelo, Hyttinen, Jari, Bisotti, Marc-Antonio, Palazzin, Alberto, Bursi, Roberta

Get full text

Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial by Nations, Kari R, Dogterom, Peter, Bursi, Roberta, Schipper, Jacques, Greenwald, Scott, Zraket, David, Gertsik, Lev, Johnstone, Jack, Lee, Allen, Pande, Yogesh, Ruigt, Ge, Ereshefsky, Larry

“…Org 26576 acts by modulating ionotropic AMPA-type glutamate receptors to enhance glutamatergic neurotransmission. The aim of this Phase 1b study (N=54) was to…”
Get full text

Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia Patients by Bursi, Roberta, Piana, Chiara, Grevel, Joachim, Huntjens, Dymphy, Boesl, Irmgard

“…Background and Objectives Lidocaine 5% medicated plaster is the first lidocaine containing product for chronic use. As no previous investigations have been…”
Get full text

Bayesian-hierarchical pharmacokinetic/pharmacodynamic (PK/PD) model to characterize the exposure-QT effect relationship for decision making in early drug development by Dubois, Vincent F.S., Boulton, Muriel, Bursi, Roberta

Get full text

Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O‐demethyl metabolite on pupil diameter and nociception in healthy subjects by Mangas‐Sanjuan, Víctor, Pastor, José Martín, Rengelshausen, Jens, Bursi, Roberta, Troconiz, Iñaki F.

“…Aim The aim of the present study was to characterize the pharmacokinetic/pharmacodynamic (PK/PD) properties of the active components of axomadol and to…”
Get full text

Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients: A Summary and Method Analysis of Bridging Research in Support of Phase II Dose Selection by Nations, Kari R., Bursi, Roberta, Dogterom, Peter, Ereshefsky, Larry, Gertsik, Lev, Mant, Tim, Schipper, Jacques

“…Background A key challenge to dose selection in early central nervous system (CNS) clinical drug development is that patient tolerability profiles often differ…”
Get full text

Translational PK–PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576 by Bursi, Roberta, Erdemli, Gul, Campbell, Robert, Hutmacher, Matthew M., Kerbusch, Thomas, Spanswick, David, Jeggo, Ross, Nations, Kari R., Dogterom, Peter, Schipper, Jacques, Shahid, Mohammed

“…Introduction The α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor potentiator Org 26576 represents an interesting pharmacological tool to…”
Get full text

Calculation of the Hyperpolarizabilities of Silicon-Based Donor−Acceptor Compounds for Nonlinear Optics by van Hutten, Paul F, Hadziioannou, Georges, Bursi, Roberta, Feil, Dirk

“…A substituted diphenyldisilane having a dimethylamino donor and a perfluoroalkylsulfonyl acceptor shows a moderate second-order nonlinear optical efficiency…”
Get full text

Design, synthesis and structure–activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate by Ratcliffe, Paul, Adam, Julia M., Baker, James, Bursi, Roberta, Campbell, Robert, Clark, John K., Cottney, Jean E., Deehan, Maureen, Easson, Anna-Marie, Ecker, Daniel, Edwards, Darren, Epemolu, Ola, Evans, Louise, Fields, Ruth, Francis, Stuart, Harradine, Paul, Jeremiah, Fiona, Kiyoi, Takao, McArthur, Duncan, Morrison, Angus, Passier, Paul, Pick, Jack, Schnabel, Peter G., Schulz, Jurgen, Steinbrede, Heinz, Walker, Glenn, Westwood, Paul, Wishart, Grant, Haes, Joanna Udo de

“…We report an expansion of the structure–activity relationship (SAR) of a novel series of indole-3-heterocyclic CB1 receptor agonists. Starting from the potent…”
Get full text

The Binding Mode of Progesterone to Its Receptor Deduced from Molecular Dynamics Simulations by Mordasini, Tiziana, Curioni, Alessandro, Bursi, Roberta, Andreoni, Wanda

“…An unambiguous understanding of the binding mode of human progesterone to its receptor still eludes experimental search. According to the X‐ray structure of…”
Get full text

A Three-Dimensional Quantitative Structure−Activity Relationship Study of Heparin-Binding Epidermal Growth Factor Shedding Inhibitors Using Comparative Molecular Field Analysis by Bursi, Roberta, Sawa, Masaaki, Hiramatsu, Yasuyuki, Kondo, Hirosato

“…Despite the lack of structural information on the heparin-binding (HB) epidermal growth factor (EGF) shedding putative target enzyme, the design of potent…”
Get full text